Dishman Pharmaceuticals and Chemicals rose 2.7% to Rs 136.95 at 14:59 IST on BSE after its Switzerland units successfully completed USFDA inspection for two sites without any adverse observations.
Meanwhile, the S&P BSE Sensex was up 115.83 points or 0.42% at 27,931.01
On BSE, so far 7.98 lakh shares were traded in the counter as against average daily volume of 1.65 lakh shares in the past one quarter. The stock hit high of Rs 143.30 and low of Rs 131.85 so far during the trading session. The stock had hit 52-week high of Rs 209.85 on 4 November 2015. The stock had hit 52-week low of Rs 79.78 on 20 July 2015. The stock had underperformed the market over the past one month till 13 July 2016, falling 7.49% compared with the Sensex's 5.37% rise. The scrip had also underperformed the market in past one quarter, sliding 23.52% as against the Sensex's 8.54% rise.
The small-cap company has equity capital of Rs 32.28 crore. Face value per share is Rs 2.
Dishman Pharmaceuticals and Chemicals' wholly owned subsidiary, namely Carbogen Amcis AG., Switzerland, has successfully completed inspection from United States Food and Drug Administration (USFDA) for its two sites located at Aarau and Neuland without any adverse observations and received the Establishment Inspection Report (EIR). Thus, now the company has these two sites in addition to Bubendorf in Switzerland, which are approved by the USFDA.
Additionally, the company's site at Naroda in Gujarat has also successfully completed USFDA inspection and received the Establishment Inspection Report (EIR).
Dishman Pharmaceuticals' consolidated net profit jumped 29.3% to Rs 49.92 crore on 3.6% fall in net sales to Rs 405.67 crore in Q4 March 2016 over Q4 March 2015.
Also Read
Dishman Pharmaceuticals acts as a full fledged CRAMS (contract research and manufacturing services) partner for global pharma innovators. It also makes phase transfer catalysts, Vitamin D, Vitamin D analogues, cholesterol, laolin related products, antiseptic and disinfectant formulations for pharmaceutical, cosmetic and related markets. The company also makes generic active pharmaceutical ingredients (API) and intermediates for the pharmaceutical industries.
Powered by Capital Market - Live News